Abstract
The aim of this study was to compare the efficacy of lamivudine vs entecavir in the prevention of hepatitis B virus (HBV) reactivation in HBV surface Ag (HBsAg)-positive patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). A total of 216 consecutive patients were enrolled and retrospectively reviewed. Of these patients, 119 received lamivudine and 97 received entecavir. The median treatment duration to complete virological response in patients with baseline HBV-DNA levels >105 copies/mL was 2.0 months in the entecavir group, significantly shorter than that of the lamivudine group. After a median follow-up of 24 months post transplantation, the cumulative incidence rates of HBV reactivation at 6, 12 and 24 months following transplantation were 3.0%, 7.0% and 24.0% in the lamivudine group, and 0%, 0% and 2.0% in the entecavir group, respectively. In addition, entecavir treatment was associated with lower cumulative incidence rates of severe hepatitis caused by HBV reactivation. Mutations leading to drug resistance were detected in 25 patients in the lamivudine group and in only one patient in the entecavir group. Our data indicate that compared with lamivudine, entecavir has more potent antiviral efficacy and may be a better choice for prophylaxis of HBV reactivation in HBsAg-positive allo-HSCT recipients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Luo Z, Xie Y, Deng M, Zhou X, Ruan B . Prevalence of hepatitis B in the southeast of China: a population-based study with a large sample size. Eur J Gastroenterol Hepatol 2011; 23: 695–700.
Fang ZL, Harrison TJ, Yang JY, Chen QY, Wang XY, Mo JJ . Prevalence of hepatitis B virus infection in a highly endemic area of southern China after catch-up immunization. J Med Virol 2012; 84: 878–884.
Francisci D, Falcinelli F, Schiaroli E, Capponi M, Belfiori B, Flenghi L et al. Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy. Infection 2010; 38: 58–61.
Mirzaee M, Yaghobi R, Ramzi M, Roshan Nia M . The prevalence of molecular and immunologic infective markers of hepatitis viruses in patients with hematological malignancies. Mol Biol Rep 2012; 39: 1217–1223.
Engels EA, Cho ER, Jee SH . Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol 2010; 11: 827–834.
Tong MJ, Hsien C, Hsu L, Sun HE, Blatt LM . Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Hepatology 2008; 48: 1070–1078.
Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline on prevention and treatment of chronic hepatitis B in China (2005). Chin Med J (Engl) 2007; 120: 2159–2173.
Cornberg M, Protzer U, Dollinger MM, Petersen J, Wedemeyer H, Berg T et al. Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection. Z Gastroenterol 2007; 45: 1281–1328.
Hsiao LT, Chiou TJ, Liu JH, Chu CJ, Lin YC, Chao TC et al. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2006; 12: 84–94.
Teh BW, Slavin MA, Szer J, Sasadeusz JJ . Hepatitis B serological changes following allogeneic bone marrow transplantation. Transpl Infect Dis 2013; 15: 98–103.
Xuan L, Huang F, Fan Z, Zhou H, Zhang X, Yu G et al. Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies. J Hematol Oncol 2012; 5: 46.
Hsu C, Tsou HH, Lin SJ, Wang MC, Yao M, Hwang WL et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology 2014; 59: 2092–2100.
Yeo W, Johnson PJ . Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209–220.
Yun J, Kim KH, Kang ES, Gwak GY, Choi MS, Lee JE et al. Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy. Br J Cancer 2011; 104: 559–563.
Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z et al. Entecavir vs lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011–1020.
Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714–1722.
Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW et al. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007; 51: 902–911.
Heo J, Park JY, Lee HJ, Tak WY, Um SH, Kim do Y et al. A 96-week randomized trial of switching to entecavir in chronic hepatitis B patients with a partial virological response to lamivudine. Antivir Ther 2012; 17: 1563–1570.
Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001–1010.
Lau GK, Leung YH, Fong DY, Au WY, Kwong YL, Lie A et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002; 99: 2324–2330.
Lau GK, He ML, Fong DY, Bartholomeusz A, Au WY, Lie AK et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002; 36: 702–709.
Locarnini S . Hepatitis B viral resistance: mechanisms and diagnosis. J Hepatol 2003; 39 (Suppl 1): S124–S132.
Gish RG, Chang TT, Lai CL, de Man R, Gadano A, Poordad F et al. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J Viral Hepat 2010; 17: 16–22.
Hui CK, Lie A, Au WY, Leung YH, Ma SY, Cheung WW et al. A long-term follow-up study on hepatitis B surface antigen-positive patients undergoing allogeneic hematopoietic stem cell transplantation. Blood 2005; 106: 464–469.
Lau GK, Liang R, Lee CK, Yuen ST, Hou J, Lim WL et al. Clearance of persistent hepatitis B virus infection in Chinese bone marrow transplant recipients whose donors were anti-hepatitis B core- and anti-hepatitis B surface antibody-positive. J Infect Dis 1998; 178: 1585–1591.
Liang R . How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 2009; 113: 3147–3153.
Ohta A, Sekimoto M, Sato M, Koda T, Nishimura S, Iwakura Y et al. Indispensable role for TNF-alpha and IFN-gamma at the effector phase of liver injury mediated by Th1 cells specific to hepatitis B virus surface antigen. J Immunol 2000; 165: 956–961.
Acknowledgements
The study was supported by grants from the National Natural Science Foundation of China (Nos. U1401221, 81270647 and 81400141) and Science and Technology Planning Project of Guangdong Province (No. 2014B020226004).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Shang, J., Wang, H., Sun, J. et al. A comparison of lamivudine vs entecavir for prophylaxis of hepatitis B virus reactivation in allogeneic hematopoietic stem cell transplantation recipients: a single-institutional experience. Bone Marrow Transplant 51, 581–586 (2016). https://doi.org/10.1038/bmt.2015.328
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2015.328
This article is cited by
-
Effectiveness of prophylactic antiviral therapy in reducing HBV reactivation for HBsAg-positive recipients following allogeneic hematopoietic stem cell transplantation: a multi-institutional experience from an HBV endemic area
Annals of Hematology (2022)
-
Hepatitis B reactivation in hematopoietic stem cell transplanted patients: 20 years of experience of a single center from a middle endemic country
Annals of Hematology (2020)
-
Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016
Annals of Hematology (2016)